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compared retrospectively: patients evaluated in a pancreatic 
MDC versus outside the MDC. Demographics, region of origin, 
disease stage, and patient retention rates (defined as >3 
encounters for pancreatic cancer), telephone encounters, 
and ED visit counts were collected using electronic health 
records. Cost information was obtained using claims data, 
and compared using Fisher’s Exact Tests. Logistic regression 
compared retention rates between the groups, correcting for 
region of origin, demographics, and disease stage. Cox 
proportional hazard models were used to calculate hazard 
ratios of death. Kaplan-Meier curves compared long-term 
survival between the two groups. 
Results: Between 2008-2010, 252 consecutive MDC patients 
were compared to 764 non-MDC patients (total N = 1100). A 
greater percentage of MDC patients traveled from non-
adjacent states (49 vs 23%, p<0.001) and had more advanced 
disease stages (10, 25, and 23% of MDC patients with 
borderline resectable, locally advanced and metastatic 
disease, respectively, versus 5, 9, and 18% of non-MDC). 
Multivariate analysis revealed that MDC patients had 2.816 
times the odds of being retained over non-MDC patients 
(p<0.001). Total charges per patient were higher for non-MDC 
patients than MDC patients and all cost subcategories were 
higher for non-MDC vs MDC patients except for outpatient 
charges (Table 1). The non-MDC group had a higher adjusted 
hazard ratio for death than the MDC group, trending toward, 
but not reaching statistical significance (HR 1.182, p=0.117). 
The MDC also had a lower rate of symptom telephone calls 
(SS) and ED visits (although NS) than the non-MDC group. At 
three years, overall survival was 20% for both MDC and non-
MDC patients (log rank p=0.845). 
Conclusions: Adjusted for region of origin, MDC patients 
were more likely to continue their care at Johns Hopkins, 
suggesting higher patient satisfaction. Total costs per patient 
were lower for MDC patients, even with a greater retention 
rate. Outpatient costs were higher for MDC patients, 
suggesting that greater outpatient engagement can supplant 
more costly inpatient encounters. Because adverse 
downstream encounters were less frequent, survival 
outcomes were at least similar for both groups, and MDC 
patients had lower costs, these data suggest multidisciplinary 
models offer care of higher value for patients with pancreatic 
cancer.  
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Purpose/Objective: Neoadjuvant chemoradiotherapy 
(NACRT) followed by surgery is the standard of care for 
locally advanced carcinoma rectum. Reassessment for surgery 
is done with an MRI scan 6-8 weeks after completion of 
NACTRT.  
The patients in whom the tumor is still inoperable, are 
usually offered palliative chemotherapy. Many oncologists 
advocate waiting upto 12 weeks for a response assessment 
MRI before declaring the disease unresectable, citing a 
possibility of delayed tumour response to radiotherapy. At 
our institute we treated these patients with further 4cycles 
of chemo and reassessed them for operability.  
Materials and Methods: Patients with locally advanced 
carcinoma rectum assessed to have unresectable disease on 
MRI at presentation received neoadjuvant radiation to a dose 
of 50 Gy in 1.8 to 2 Gy daily fractions with concurrent 
capecitabine chemotherapy 825 mg/m2 daily. A follow up MRI 
was done 6 weeks after completion of NACRT and assessed in 
a joint multidisciplinary meeting. Those with persisting 
unresectable local disease were planned for 4 cycles of 
chemotherapy followed by reassessment imaging for 
resectability. We present the results of the patients with 
poor response to NACTRT having further treated by the 
chemotherapy.  
Results: From Jan 2013 till September 2014, 39 patients with 
unresectable rectal cancer recieving NACRT were still found 
to have unresectable disease on MRI. They were planned for 
further chemotherapy with FOLFIRINOX or FOLFOX based 
regimens. Thirty six patients completed at least 4 cycle of 
chemotherapy and one patient defaulted. At the time of 
submission of this abstract, 24 patients had good regression 
of disease which was evident on MRI and 17 (45%) patients 
underwent R0 resection. Seven patients who still had 
unresectable disease and 2 which developed distant 
metastasis were given further palliative chemotherapy. Seven 
patients are scheduled for reassessment after followup 
imaging. One patient was lost to follow-up and 1 died due to 
sepsis. Two patients had complete pathological response. 
Among the 17 successfully operated patients, 8 had received 
FOLFIRINOX while 1 had received FOLFOX and 8 patients 
received CAPOX chemotherapy.  
Conclusions: Achieving margin negative resection in these 
patients is an encouraging starting point for further research 
in this subset. Whether this continued decrease in primary 
tumour volume can be attributed to delayed response to 
radiotherapy or addition of further chemotherapy, or both, is 
yet to be ascertained. Hence for patients with advanced local 
disease not yet in palliative stage, further intensive 
chemotherapy with clinicoradiological follow-up should be 
done to facilitate successful surgical resection.  
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Purpose/Objective: 
Objective: Patients with locally recurrent rectal cancer have 
severe morbidity and poor quality of life. Most are ineligible 
for surgery, and combined re-irradiation and chemotherapy 
provides limited symptom palliation and tumor control [1]. 
Clinical data suggests that adding hyperthermia to radiation 
improves tumor response [2]. However, past studies used 
invasive temperature sensors that were poorly tolerated and 
provided insufficient thermal dosimetry. 
The objective of this study was to evaluate the feasibility in 
pigs of using MRI-HIFU to achieve mild hyperthermia in 
normal tissue targets that match typical locations for 
recurrent rectal cancer; and the quality of MR thermometry 
in consenting volunteers with biopsy-proven primary rectal 
cancer. 
Materials and Methods: 
Preclinical validation: 
The feasibility of MR-HIFU hyperthermia was evaluated in a 
swine model (N=6, study approved by the Local Animal Care 
Committee). Imaging and hyperthermia were performed using 
a clinical MRI (Achieva 3T, Philips Healthcare) with an 
integrated MR-HIFU system (Sonalleve, Philips Medical 
Systems). Different targets at thigh muscle (at the rectal wall 
and deep locations) were evaluated. Thermal maps were 
acquired in 6 slices along the beam were obtained every 3.2s. 
Sonications were prescribed with 18 mm diameter treatment 
regions at 1MHz with target temperature of 42-42.5°C, for 
10-60 min.  
Human imaging study  
The quality of MR thermometry of rectal cancers using MR-
HIFU was evaluated with an imaging-only study (no heating) 
including 6 consenting volunteers with rectal cancer. This 
study was approved by the Sunnybrook Research Ethics 
Board. Anatomical and MR thermometry images were 
acquired using the same MRI and MR-HIFU system and 
parameters as in the preclinical study. In 3/6 subjects, rectal 
filling with 200-300 mL of saline was used to reduce motion-
related artefacts in MR thermometry. Thermometry was 
performed in imaging slices located at the tumor. 
Results: Mean target temperature in the animal study 
matched the desired hyperthermia temperature to within 
0.2°C, varying temporally with a standard deviation of 0.5°C 
or lower. No evidence of tissue changes were observed on 
contrast-enhanced imaging or at necropsy. The imaging study 
with patients showed that MR-based temperature remained 
stable especially when rectal filling was used to reduce bowel 
motion. 
Figure 1. 
Figure 2. 
 
Conclusions: Our preclinical validation study demonstrated 
that MR-HIFU can safely deliver mild temperatures of 41 to 
43°C in a targeted volume for 30 minutes. Our clinical 
imaging study illustrates that with careful patient selection 
and preparation, the current MR-HIFU system may provide 
adequate treatment depth to target recurrent rectal cancers 
and sufficient MR temperature mapping stability for real-time 
control of mild hyperthermia exposures.  
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Purpose/Objective: Aim of this study is the evaluation of 
feasibility and efficacy of SBRT in the treatment of 
unresectable hepatocellular carcinoma (HCC). 
Materials and Methods: Patients with 1-3 inoperable HCC 
lesions with diameter ≤6cm were treated by SBRT. 
